Insider trade

Passage Bio (PASG): CEO received 58K units

William Chou, CEO at Passage Bio, reported a grant / award of 58K units.

58K
Derivative units
Traded
Mar 16, 2026
Filed
Mar 19, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 3, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  2. Mar 4, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement

What came next

  1. Apr 28, 2026Company filing · Form 8-K · RestructuringAnnounced job cuts, closures or a restructuring“As part of its previously announced efforts to review strategic alternatives to maximize shareholder value, on April 28, 2026, Passage Bio, Inc. (the “ Company ”) announced a restructuring of its workforce (the “ Restructuring Plan ”) to decrease its operating expenses by reducing the workforce by approximately 75%.”
  2. May 21, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
  3. Jun 23, 2026Company filing · Form 8-K · Material agreement, Agreement endedControl of the company changed hands, and changed a top executive or board member (and 5 more items)“On June 24, 2026, Passage Bio and Remix issued a joint press release announcing the execution of the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference.”
  4. Jun 25, 2026Insider10% owner purchased ~$206K of PASG shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Passage Bio

OQRO holds no insider, Congress, fund or contract record for Passage Bio dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PASG page.

Other recent filings by William Chou, PRESIDENT AND CEO

The full history of William Chou, PRESIDENT AND CEO is on the profile page.

How this filing works

Explore the data

Common questions

Which Passage Bio (PASG) insider traded, and how much?

William Chou, CEO at Passage Bio, reported a grant / award of 58K units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Mar 16, 2026. Filed: Mar 19, 2026. That is 3 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean PASG stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Passage Bio

Everything OQRO holds on this company is on its PASG page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data